Stock LRMR LARIMAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
8 USD +12.68% Intraday chart for Larimar Therapeutics, Inc. +12.99% +75.82%
May. 31 Health Care Stocks Climb On Drug News -- Health Care Roundup DJ
May. 31 Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Health Care Stocks Climb On Drug News -- Health Care Roundup
DJ
Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program
DJ
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
AQ
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
AQ
United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
CI
Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
Investors Tread Cautiously as Nvidia Earnings Loom, Driving Muted Premarket Action for US Equity Futures
MT
Sector Update: Health Care
MT
Top Premarket Gainers
MT
Larimar Therapeutics Gets Partial Hold Lifted on Study of Nervous System Disorder Treatment; Shares Soar Premarket
MT
Larimar Therapeutics Gets Partial Hold Lifted on Study of Nervous System Disorder Treatment
MT
Larimar Therapeutics Shares Up 22%, FDA Lifts Hold for Nervous System Disorder Treatment
DJ
Larimar Therapeutics Announces FDA Has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich?S Ataxia
CI
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
AQ
Larimar: Q1 Earnings Snapshot
AQ
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
AQ
Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
North American Morning Briefing : Stock Futures -2-
DJ
Larimar: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LRMR Stock
  4. News Larimar Therapeutics, Inc.